Barclays analyst Lauren Lieberman maintained a Hold rating on Procter & Gamble (PG – Research Report) today and set a price target of

In a report released today, Lauren Lieberman from Barclays maintained a Buy rating on Keurig Dr Pepper (KDP – Research Report), with a price

Oakmark Funds, advised by Harris Associates, released its “Oakmark Select Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund returned 6.01% in the fourth quarter compared to a 2.

Keurig Dr Pepper's KDP short percent of float has risen 25.75% since its last report. The company recently reported that it has 22.25 million shares sold short, which is 2.1% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.08 days to cover their short positions on average.

ATLANTA, GEORGIA / ACCESS Newswire / / GAINSystems, a leader in supply chain performance optimization software, today announced its greatest year yet. Rapid results and outcomes drove a record-breaking number of new customers and

Report on how AI is driving market transformation - The global FMCG market size is estimated to grow by USD 456.6 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 3.

Circular Action Alliance (CAA), a Producer Responsibility Organization (PRO) dedicated to implementing effective Extended Producer Responsibility (EPR)

Conagra Brands and Georgia-Pacific have joined the producer responsibility organization's board.

It wasn’t until there was a recall on Diamond Pet Foods that I learned that other companies were making Costco brands. You see, in that recall notice that Diamond put out, it included Costco’s Kirkland Signature dog food.

In a report released yesterday, Robert Ottenstein from Evercore ISI maintained a Buy rating on Procter & Gamble (PG – Research Report),

Keurig Dr Pepper Inc. closed 18.29% short of its 52-week high of $38.28, which the company reached on September 24th.

Keurig Dr Pepper (NASDAQ:KDP – Free Report) had its price objective trimmed by Barclays from $39.00 to $36.00 in a research note issued to investors on Friday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.